HER2-targeted antibody-drug conjugate that binds HER2, is internalized, and releases an intracellular cytotoxic payload; the antibody component also inhibits HER2 signaling and mediates ADCC.
HER2-targeted ADC that binds HER2 and is internalized; a cleavable linker releases the MMAE payload, which inhibits tubulin polymerization causing G2/M arrest and apoptosis; the antibody component also blocks HER2 signaling and mediates ADCC.
The ADC binds HER2, is internalized, and releases MMAE that inhibits tubulin polymerization causing G2/M arrest and apoptosis; the antibody Fc can also trigger ADCC against HER2-expressing cells.
An anti-HER2 IgG1 monoclonal antibody that binds domain II of HER2 and blocks HER2 dimerization, especially HER2/HER3.
Humanized IgG1 monoclonal antibody targeting HER2 domain II to block HER2 dimerization—particularly HER2/HER3—thereby inhibiting downstream ERBB signaling (PI3K/AKT, MAPK) and inducing growth arrest/apoptosis; Fc engagement can also trigger ADCC.
IgG1 antibody binds HER2 and recruits FcγR-expressing effector cells (e.g., NK cells) to kill via ADCC; HER2 dimerization blockade also suppresses survival signaling, promoting apoptosis.
HER2-targeted antibody-drug conjugate linking trastuzumab to the microtubule inhibitor DM1; after HER2 binding and internalization, DM1 disrupts microtubules while trastuzumab retains HER2 blockade and ADCC.
HER2-targeted antibody–drug conjugate linking trastuzumab to the microtubule inhibitor DM1 via a nonreducible linker. After HER2 binding and internalization, intracellular DM1 disrupts microtubule dynamics to inhibit cell division and induce apoptosis, while the trastuzumab component blocks HER2 signaling and mediates Fc-dependent ADCC.
The ADC binds HER2 on target cells, is internalized, and releases DM1 intracellularly to inhibit microtubules, causing mitotic arrest and apoptosis; trastuzumab Fc can also mediate ADCC against HER2+ cells.
An anti-CD38 IgG1 monoclonal antibody that mediates ADCC, CDC, ADCP, direct apoptosis, and immune modulation, including depletion of CD38+ immunosuppressive cells.
Human IgG1k monoclonal antibody targeting CD38; binding to CD38 on malignant plasma cells triggers immune effector–mediated killing (ADCC, ADCP, CDC) and direct apoptosis, and depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing anti-tumor immunity.
Daratumumab binds CD38 on target cells and triggers NK cell ADCC, macrophage ADCP, and complement-dependent cytotoxicity; Fc crosslinking can also induce direct apoptosis of CD38+ cells.
Monoclonal antibody targeting Claudin 18.2 on tumor cells, promoting ADCC and CDC against CLDN18.2-expressing gastric/GEJ cancer cells.
ASKB589 is an unconjugated monoclonal antibody against Claudin 18.2. By binding CLDN18.2 on tumor cells, it triggers Fc-mediated immune effector functions—antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)—resulting in selective killing of CLDN18.2-positive gastric/GEJ cancer cells.
Binds CLDN18.2 on target cells and engages immune effectors via Fc to induce ADCC and complement activation (CDC), causing lysis of CLDN18.2-positive cells.